image goes here
Study Startup Success for the New Generation of Genetically Engineered Vaccines
The global COVID-19 pandemic has brought vaccine research to the forefront, and a surge of research involving genetically engineered vaccines is currently taking place. The availability of the viral genome and current genetic engineering techniques provide a wealth of opportunities for research and development of new vaccines. The most prominent COVID-19 vaccine candidates contain engineered genetic material, and gene-based cancer vaccines and genetically engineered immunotherapies are also booming.
However, studies involving investigational products containing engineered genetic materials also pose unique startup challenges. In this webinar, Advarra Director of Biosafety Services Daniel Eisenman introduces the latest trends in genetically modified vaccine and immunotherapy studies. His presentation also explores obstacles to study startup and strategies to keep research moving forward.
Learning Objectives:
- Describe current trends in genetically modified vaccines and immunotherapy research
- Identify study startup obstacles for these studies
- Outline strategies for overcoming challenges in research involving genetic engineering
Presented By

Daniel Eisenman
PhD, RBP, SM(NRCM), CBSP
Director of Biosafety Services
Advarra
NA
NA
NA
NA
NA
NA

NA
NA
NA
DATE: July 8, 2020
Time: 1 pm ET | 10 am PT
Duration: 1 hour